BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,129,648 | +4148.6% | 308,292 | +2671.2% | 0.01% | – |
| Q2 2023 | $191,350 | +2.9% | 11,125 | +2.6% | 0.00% | – |
| Q1 2023 | $185,992 | +122.5% | 10,845 | -1.1% | 0.00% | – |
| Q4 2022 | $83,591 | -97.5% | 10,970 | -96.7% | 0.00% | -100.0% |
| Q3 2022 | $3,344,000 | +10.5% | 336,426 | +0.9% | 0.00% | +50.0% |
| Q2 2022 | $3,027,000 | -11.4% | 333,368 | -0.9% | 0.00% | 0.0% |
| Q1 2022 | $3,416,000 | -0.6% | 336,532 | +63.3% | 0.00% | 0.0% |
| Q4 2021 | $3,437,000 | -71.7% | 206,067 | -20.6% | 0.00% | -75.0% |
| Q3 2021 | $12,159,000 | -23.2% | 259,416 | -0.2% | 0.01% | -27.3% |
| Q2 2021 | $15,839,000 | +3.3% | 259,824 | +4.4% | 0.01% | 0.0% |
| Q1 2021 | $15,326,000 | -14.8% | 248,798 | -1.6% | 0.01% | -21.4% |
| Q4 2020 | $17,981,000 | +114.9% | 252,865 | +13.4% | 0.01% | +100.0% |
| Q3 2020 | $8,366,000 | +30.7% | 222,967 | +13.6% | 0.01% | +16.7% |
| Q2 2020 | $6,399,000 | – | 196,241 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |